Details for Patent: 9,526,703

✉ Email this page to a colleague

Which drugs does patent 9,526,703 protect, and when does it expire?

Patent 9,526,703 protects BONJESTA and is included in one NDA.

This patent has thirty-two patent family members in twenty-seven countries.

Summary for Patent: 9,526,703

Title:	Plurimodal release formulation of doxylamine and pyridoxine and/or metabolites or salts thereof
Abstract:	A solid oral dosage form comprising a core comprising a doxylamine component and a pyridoxine component coated with an enteric coating is disclosed. The solid oral dosage form further comprises two active ingredient-containing coatings surrounding the enteric coating, the active ingredient-containing coatings being separated from one another by an intermediate coating, and one of the two active ingredient-containing coatings comprising a doxylamine component and being free of a pyridoxine component, and the other of the two active ingredient-containing coatings comprising a pyridoxine component and being free of doxylamine component. Uses of the solid oral dosage form for the alleviation of the symptoms of nausea and vomiting, for example in the case of nausea and vomiting of pregnancy (NVP), are also disclosed.
Inventor(s):	Vranderick; Manon (St-Lazare, CA), St-Onge; Jean-Luc (Mirabel, CA), Gallo; Michele (Blainville, CA), Gervais; Eric (Blainville, CA)
Assignee:	Duchesnay Inc. (Blainville, CA)
Application Number:	14/839,859
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 9,526,703
Patent Claim Types: see list of patent claims	Use; Compound; Dosage form;

Drugs Protected by US Patent 9,526,703

Glossary

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Duchesnay	BONJESTA	doxylamine succinate; pyridoxine hydrochloride	TABLET, EXTENDED RELEASE;ORAL	209661-001	Nov 7, 2016		RX	Yes	Yes	⤷ Sign Up	⤷ Sign Up	Y			TREATMENT OF NAUSEA AND VOMITING OF PREGNANCY IN WOMEN WHO DO NOT RESPOND TO CONSERVATIVE MANAGEMENT	⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

Foreign Priority and PCT Information for Patent: 9,526,703

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
	PCT/CA2014/050828	Aug 29, 2014

International Family Members for US Patent 9,526,703

Subscribe to access the full database, or Sign Up
Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	101728	⤷ Sign Up
Australia	2014405049	⤷ Sign Up
Brazil	112017004190	⤷ Sign Up
Canada	2920247	⤷ Sign Up
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.